—·
Liquid biopsy, MRD, and AI diagnostics are accelerating. The bottleneck is coverage evidence: what signal is actionable, and who pays when it changes treatment.
A patient can already have a ctDNA or cfDNA test ordered and receive a molecular readout. The hard part comes next: whether the result can actually change therapy, once reimbursement and evidence standards get involved. When tumor-agnostic or monitoring-focused claims don’t match payer expectations built on prospectively proven treatment benefit, momentum stalls despite good diagnostics.
The regulatory framework underlying precision diagnostics isn’t the sole culprit. In the US, FDA’s companion diagnostic (CDx) approach ties the device to a therapeutic decision pathway, including how to develop and label in vitro companion diagnostics for oncology therapeutics. (FDA CDx guidance for oncology) In Europe, the European Medicines Agency (EMA) similarly frames personalized medicine in oncology around companion diagnostics development lifecycle and regulatory expectations. (EMA personalised medicine oncology overview, EMA concept paper: development lifecycle)
Still, “precision medicine” is broader than a single device-label match. It includes tumor-agnostic testing, pharmacogenomics that changes drug choice, MRD (measurable residual disease) signals used to monitor response, and AI diagnostic interpretation that may evolve as models are updated. Coverage rules were largely built for narrower clinical claims. The result is an evidence squeeze: assay performance can improve, but clinical utility evidence can arrive too late for reimbursement timing.
Precision medicine relies on multiple biomarker signals. A liquid biopsy is a diagnostic test performed on body fluids, most often blood. Its target may be ctDNA (circulating tumor DNA, fragments shed by tumors) or cfDNA (cell-free DNA, a broader category of DNA fragments from multiple tissues). MRD is used to detect residual disease after treatment, where a “positive” signal is interpreted as higher risk of recurrence. These categories are not interchangeable. A signal can be analytically accurate and still be non-actionable for payers unless it predicts a clinically meaningful outcome and drives a treatment change that improves it.
That’s where evidence packages often fall short--not because trials don’t measure outcomes, but because they measure the wrong endpoints for coverage. Payers don’t reimburse “biomarker accuracy.” They reimburse a decision. For tumor-agnostic and monitoring-focused claims, the core question becomes whether testing changes what clinicians do--and whether that shift improves patient-relevant endpoints.
The most common friction: trials supporting detection or prognostic utility don’t provide the prospective, test-driven management pathway payers need for “coverage with conditions” or unconditional reimbursement.
FDA’s biomarker qualification program frames qualification as a structured pathway to support the use of a biomarker in drug development, including drug development tools (DDTs) used to measure and interpret biomarkers reliably. (FDA biomarker qualification overview, FDA biomarker guidances and reference materials, Qualification process for drug development tools PDF)
Qualification establishes that the biomarker can be used for a defined context of use--for example, as a measurement tool supporting decisions in a specific development program. It does not automatically satisfy the coverage question payers ask: whether the biomarker result improves outcomes in routine care by driving specific management changes.
Context matters enough that it helps to split “actionability” into two operational components coverage committees can interrogate:
For tumor-agnostic or monitoring-focused liquid biopsy claims, “context of use” is decisive. A test that reports a ctDNA level may support prognosis, surveillance intensity, or clinical trial enrollment. Payers, though, typically anchor payment to specific decisions: which therapy is started, switched, or withheld because of the test. Regulatory guidance for companion diagnostics frames development and labeling around oncology therapeutic decisions, not just detection. (FDA CDx guidance for oncology therapeutics)
So what for decision-makers: insist that “actionable” be operationalized at the policy level, not left as a clinical inference. When approving or reimbursing precision diagnostics, agencies and payers should require applicants to (a) specify the precise clinical decision triggered by the biomarker result and (b) provide evidence comparing test-guided management versus standard management for patient-relevant endpoints (not just biomarker shifts). Without that, the evidence package may be scientifically credible yet economically non-coverable, because payers can’t map the claim onto a reimbursable workflow decision.
Evidence bottlenecks don’t live only in trials. Workflows are where they surface. Liquid biopsy and AI diagnostic interpretation must integrate into ordering pathways, laboratory turnaround times, and confirmatory testing expectations when results guide treatment changes.
Regulators have recognized that diagnostics don’t operate in isolation. Companion diagnostics are typically in vitro tests paired with a therapy’s development and labeling. FDA’s companion diagnostics program is designed to coordinate how diagnostics support drug use. (FDA companion diagnostics page) On the medical device side, FDA provides guidance for in vitro companion diagnostic devices for industry and FDA staff, emphasizing procedural and operational considerations expected for CDx intended use. (FDA in vitro companion diagnostic devices guidance PDF)
Europe’s approach is similarly procedural. EMA materials and scientific guidance address how companion diagnostics should be developed within a personalized medicine lifecycle, including procedural aspects involving stakeholders such as notified bodies for the device side. (EMA concept paper: development lifecycle, EMA procedural guidance consultation PDF, EMA expert group on CDx)
Two real-world pressures then decide whether the promise can be used safely: confirmatory testing and lab logistics. If a ctDNA result triggers an MRD-driven treatment modification, then ambiguous or technically borderline results need a confirmatory workflow. Otherwise, a precision strategy can amplify operational uncertainty--more patients measured, but fewer decisions safe enough to act on.
Reimbursement is sensitive to operational risk. A payer can reject coverage if the intended claim requires confirmatory steps or repeat sampling that isn’t priced, covered, or supported in care pathways. FDA’s drug development tools qualification framework similarly emphasizes that reliability is tied to a defined use context. (Qualification process for drug development tools PDF)
So what for decision-makers: treat “workflow evidence” as part of clinical utility. For liquid biopsy and AI-guided interpretation, require applicants (and clinical sites they partner with) to submit a use-context description covering ordering, reporting, confirmatory testing triggers, and the expected turnaround time window needed to make a therapy decision. Regulators can condition labeling claims; payers can tie coverage to fulfillment of that context.
AI diagnostic evidence raises a governance problem distinct from analytic accuracy. An algorithm can be clinically useful at one point in time and then change. Even if the lab process stays constant, a model update can shift interpretation thresholds, risk scores, or classification boundaries. This isn’t hypothetical. FDA’s device regulatory approach for companion diagnostics reflects that labeling must correspond to the intended use of the test. When intended interpretation changes, governance must change too.
FDA guidance on developing and labeling in vitro companion diagnostic devices for oncology therapeutics is grounded in tying test performance to clinical claims. (FDA CDx guidance for oncology therapeutics) EMA’s companion diagnostics ecosystem similarly structures evidence around the personalized medicine lifecycle. (EMA concept paper: development lifecycle)
The reimbursement implication is increasingly direct: if the model evolves, what stays stable? Payers may demand assurances that clinical utility evidence remains valid after updates. Regulators may require documentation about software changes and their impact on performance. Europe’s procedural guidance and the involvement of CDx expert groups highlight that lifecycle matters, not just initial approval. (EMA procedural guidance consultation PDF, EMA expert group on CDx)
A policy bottleneck appears when reimbursement decisions move faster than model governance. Coverage might be granted for a specific version, while procurement and clinical integration lag. Meanwhile, clinical practice may adopt updates before payers or regulators have clear boundaries for how evidence can be extrapolated.
So what for decision-makers: demand “evidence continuity” commitments for AI-enabled diagnostics. Specifically, require sponsors to define how they will validate clinical performance after model updates, how changes will be communicated, and what evidence standard applies to small versus large updates. Without these rules, reimbursement becomes a moving target that discourages cautious adoption.
AACR 2026 liquid biopsy and cell-free DNA momentum (as reflected in open press materials) points toward platforms emphasizing detection and monitoring advances. These announcements typically frame outcomes as tumor-agnostic detection, MRD monitoring, or operational improvements in cfDNA workflows. (PR Newswire, Delfi Diagnostics AACR 2026 announcement)
But press announcements are not clinical utility evidence. They rarely include the prospective, test-guided management design payers require when results trigger therapy changes. The same innovation can feel “real” to clinicians at a conference and “unreimbursable” in a coverage memo. Structurally, a diagnostic can demonstrate analytical improvement--lower limits of detection, better classification, faster turnaround--yet still lack the specific comparative evidence a coverage committee treats as the bridge from measuring to treating.
To translate AACR-style momentum into coverage readiness, decision-makers should look past the assay headline and interrogate the evidence architecture. The key questions are:
These elements mirror regulatory “context of use” logic--now with a payer lens: coverage committees want to see how the test changes a reimbursable decision and improves outcomes under that pathway.
Regulatory qualification pathways can help sponsors structure evidence, but they don’t remove payer requirements. FDA’s qualification process for drug development tools sets expectations for defined uses and evidence generation. (Qualification process for drug development tools PDF) Coverage decisions still typically demand evidence that patients benefit in routine practice.
So what for decision-makers: establish an explicit “coverage evidence ladder.” For liquid biopsy and AI diagnostic claims, define in advance what study types qualify for prospective coverage (clinical utility tied to management changes), what can be accepted as real-world evidence (RWE) under conditional coverage, and when the threshold resets if the test evolves. That approach makes AACR-style innovation legible to reimbursement cycles.
Precision medicine isn’t only scientific--it’s an evidence procurement system. Costs accumulate when evidence delivery is delayed because reimbursement pathways are uncertain and regulatory labeling doesn’t automatically translate into payer coverage.
Regulators formalize evidence tool usage in ways that show why structure matters. FDA’s biomarker qualification program outlines pathways for establishing biomarker credibility for specific contexts, including publicly described guidance and a qualification process document that standardizes what evidence looks like. (FDA biomarker qualification overview, Qualification process for drug development tools PDF) These processes exist because evidence must be structured for downstream regulatory and scientific decisions. But payers often require stronger linkage to clinical outcomes driven by management changes.
A credible way to quantify delay costs requires more than the existence of public guidance artifacts. Without adoption, coverage, or time-to-coverage datasets, the piece risks substituting institutional process for economic impact. A defensible approach is to model delay costs as an interval between (1) a test’s labeling or technical readiness and (2) the first payer coverage policy that reimburses test-guided management.
Decision-makers can operationalize that interval using three concrete time-stamped events (assembled from public and internal records):
With these timestamps, “delay cost” becomes the product of (a) the coverage gap duration and (b) the expected volume of eligible patients and eligible decision points (e.g., MRD assessment timepoints or ctDNA monitoring cycles), adjusted for the incremental cost of the test and downstream treatment consequences. This turns a “delay tax” from metaphor into a spreadsheetable KPI.
So what for decision-makers: replace narrative quantification with measurable intervals. Build an evidence-to-coverage dashboard for each indication: track time from regulatory readiness to payer coverage to clinical workflow adoption, then attach patient-volume estimates to each decision moment. That makes it possible to see where the bottleneck lies--and quantify value lost during each unpriced, un-evidenced decision gap.
The precision medicine reimbursement bottleneck is easiest to see in named systems: how they behave when evidence is incomplete or misaligned with intended use. The materials here are regulatory and procedural, so the “cases” below are governance case studies based on documented regulatory pathways and companion diagnostic lifecycle structures rather than private trial anecdotes.
In FDA’s biomarker qualification pathway, the context of use is explicit: sponsors define the biomarker’s role for drug development tools, supported by evidence expected in qualification. This is a governance “case” because it determines whether a biomarker can be used in a particular setting, limiting uncontrolled extrapolation. The qualification framework is documented in FDA’s qualification process materials. (Qualification-Process-for-Drug-Development-Tools PDF)
Outcome: sponsors get clarity on the evidentiary standard required for the defined purpose. Payers downstream still may require clinical utility tied to management changes, but the evidence base is less ambiguous.
Timeline anchor: the qualification process structures how defined evidence expectations are agreed within the program’s established materials. (FDA biomarker qualification overview, FDA biomarker guidances and reference materials)
EMA’s companion diagnostics lifecycle guidance and procedural consultation materials show how device and therapeutic evidence is coordinated. The concept paper on development lifecycle for personalized medicines and companion diagnostics signals that lifecycle management is part of evidence acceptability. (EMA concept paper: development lifecycle) The procedural consultation guidance describes procedural aspects with notified bodies. That governance detail can influence when evidence is considered complete. (EMA procedural guidance consultation PDF)
Outcome: a more predictable governance path for companion diagnostic evidence, which should reduce the gap between “device performance” and “decision relevance.”
Timeline anchor: the lifecycle approach is framed as development and procedural governance, not a one-time submission moment. (EMA personalised medicine oncology overview)
So what for decision-makers: build reimbursement evidence alignment using the same logic regulators use. Define context of use, coordinate evidence expectations early, and avoid treating “detection” as the same as “clinical action.” Even without detailed trial narratives here, the documented regulatory pathways show where ambiguity is reduced.
The funding question isn’t an afterthought. Precision medicine expands the number of times patients are measured and increases the probability that therapy will be adjusted based on biomarker signals. Costs shift across the system: more testing upstream, fewer “known” costs downstream, and potentially higher drug costs if biomarker triggers therapy intensification.
In practice, reimbursement coverage is fragmented. In the US, coverage decisions can differ across Medicare, Medicaid, and private payers. The provided sources focus on regulatory frameworks rather than payer-by-payer price schedules, so this article doesn’t claim a specific Medicare coverage rule. What can be grounded in the provided regulatory documents is the principle that clinical claims for companion diagnostics require a tight link to therapeutic decisions.
FDA’s oncology CDx guidance frames development and labeling around specific therapeutic use, which is where payer reimbursement tends to attach. (FDA CDx guidance for oncology therapeutics) EMA’s personalized medicine oncology and companion diagnostic lifecycle materials similarly frame governance around coordination between diagnostics and therapeutics. (EMA personalised medicine oncology overview, EMA concept paper: development lifecycle)
The policy challenge is paying for monitoring and MRD strategies when the biomarker is used to guide when to switch or stop therapy. Monitoring can be clinically valuable even when the biomarker doesn’t map neatly to a single drug label. Payers, however, often require evidence that the monitoring strategy leads to better outcomes in a way they can reimburse.
So what for decision-makers: create a coverage pathway for monitoring-linked precision diagnostics that is conditional and evidence-upgradable. Regulators and payers should allow coverage based on defined interim evidence with a commitment to prospective data collection, especially when claims are tumor-agnostic or MRD-focused.
Moving beyond the evidence bottleneck requires governance that is specific, testable, and version-aware.
First, agencies should require explicit definitions of clinical action thresholds: what counts as actionable signal, how it maps to patient management, and what confirmatory testing is needed before a treatment decision. This aligns with the principle that biomarkers and drug development tools must have defined context of use. (FDA biomarker qualification overview, Qualification process for drug development tools PDF)
Second, payers should demand a two-stage evidence plan for tumor-agnostic and monitoring-focused liquid biopsy. Stage one can use analytical validity and early clinical endpoints, but stage two must demonstrate clinical utility tied to management changes. FDA’s companion diagnostics framework emphasizes tying diagnostic claims to therapeutic decision-making. (FDA companion diagnostics, FDA in vitro companion diagnostic devices guidance PDF)
Third, AI interpretation needs a governance standard for evolution. Sponsors should document how updates preserve clinical validity, and payers should cover only versions tied to the evidence submitted under the defined context of use. EMA’s companion diagnostic lifecycle concept paper is one route to institutionalize that lifecycle thinking. (EMA concept paper: development lifecycle)
So what for decision-makers: act now on three concrete levers.
Because the bottleneck is structural, the fix is likely structural too. Within roughly 18 to 30 months from now (by late 2027), the most realistic shift is that coverage pathways will increasingly separate “detection” claims from “management-change” claims, while demanding versioned evidence for AI interpretations. That timeline follows the logic regulators already require: defined context of use and procedural lifecycle coordination for companion diagnostics and biomarker tools, which takes time to operationalize across sponsors, labs, and payers. (FDA biomarker qualification overview, EMA concept paper: development lifecycle)
What investors should watch is not only assay performance announcements at conferences like AACR, but whether sponsors lock down clinical utility evidence packages that can survive payer scrutiny. What regulators should watch is whether “actionable signal” is defined well enough that coverage can be justified without clinicians inferring thresholds in the dark. What institutions should watch is whether ordering and confirmatory testing workflows align with how evidence was generated and how the test is labeled.
By late 2027, make precision medicine coverage depend on a named clinical decision and a versioned interpretation governance plan; if the signal can’t be tied to a specific management change with evidence, it won’t be reimbursement-ready.
Digital health AI claims succeed or fail on evidence plumbing: provenance, intended use boundaries, clinical evaluation design, and post-market monitoring readiness.
RAPID promises faster Medicare coverage, but the real timeline hinges on how device evidence, data governance, and software change control synchronize for audit.
RAPID accelerates Medicare-coverage decisions, but only products with interoperability, cyber resilience, and audit trails will keep scaling. By 2027, investors should require evidence-ready architectures, not just pilots.